Showing results (361-370 of 831) with videos related to

Sort By:
Pageof 84
Cancer Genetics and Cytogenetics|June 2, 2006
Loss of TP53 is due to rearrangements involving chromosome region 17p10 approximately p12 in chronic lymphocytic leukemiaStephanie R Fink, Stephanie A Smoley, Kimberly J Stockero, et al.
Haematologica|April 24, 2024
Monocyte response to SARS-CoV-2 protein ORF8 is associated with severe COVID-19 infection in patients with chronic lymphocytic leukemiaGordon J Ruan, Xiaosheng Wu, Kimberly A Gwin, et al.
British Journal of Haematology|April 7, 2009
Risk of non-Hodgkin lymphoma in association with germline variation in complement genesJames R Cerhan, Anne J Novak, Zachary S Fredericksen, et al.
Acta Haematologica|July 24, 2019
Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903)Sanford Kempin, Zhuoxin Sun, Neil E Kay, et al.
Cancer|January 26, 2006
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcomeHagop Kantarjian, Susan O'brien, Jorge Cortes, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosisSrdan Verstovsek, Ayalew Tefferi, Jorge Cortes, et al.
Cancer|December 19, 2007
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?Hagop Kantarjian, Susan O'Brien, Jianqin Shan, et al.
Biomed Research International|February 6, 2015
Phase II, open label, randomized comparative trial of ondansetron alone versus the combination of ondansetron and aprepitant for the prevention of nausea and vomiting in patients with hematologic malignancies receiving regimens containing high-dose cytarabineTalha Badar, Jorge Cortes, Gautam Borthakur, et al.
Leukemia & Lymphoma|December 12, 2022
Time to second treatment can be used to predict overall survival in chronic lymphocytic leukemia: identifying risk factors to help guide treatment selectionKurt S Bantilan, Neil E Kay, Sameer A Parikh, et al.
British Journal of Haematology|April 4, 2008
Prognostic importance of T and NK-cells in a consecutive series of newly diagnosed patients with chronic lymphocytic leukaemiaShanique Palmer, Curtis A Hanson, Clive S Zent, et al.
Pageof 84